Abstract
Famotidine (Pepcid, a histamine-2 receptor blocker, is marketed for the treatment of peptic ulcer disease, gastroesophageal reflux, and the treatment of pathological hypersecretory conditions, including the Zollinger-Ellison syndrome. Recent reports indicate that it is also effective in relieving the deficit (or withdrawal) symptoms of adults with schizophrenia. Autism, a neuropsychiatric disorder which presents within the first few years of life, is defined by deficient social interaction, communication, language, play, and a markedly restricted repertoire of activities and interests. Similarities between the deficit symptoms of schizophrenia and the social deficit symptoms of autism suggest the hypothesis that famotidine may be useful in treating children with autism. Histamine serves as a neurotransmitter and neuromodulator in the brain. H2-receptors in the brain predominantly transmit inhibitory signals; when these receptors are stimulated in animals, spontaneous activity and exploratory behavior decrease; blockade of H2-receptors would therefore be expected to reverse this inhibition.
References
Sep 1, 1992·Digestive Diseases and Sciences·A CarroccioA Notarbartolo
May 1, 1992·The American Journal of Psychiatry·N D VolkowF Henn
Sep 1, 1991·Trends in Neurosciences·H WadaT Watanabe
May 1, 1991·Journal of Clinical Anesthesia·M NishimuraC Tashiro
Jul 1, 1991·Acta Anaesthesiologica Scandinavica·J S JahrD R Cook
Jun 2, 1990·Lancet·R KaminskyM Davidson
May 1, 1991·The Journal of Pediatrics·W R TreemJ S Hyams
Jan 1, 1985·European Journal of Clinical Pharmacology·T TakabatakeN Hashimoto
Dec 1, 1994·The Journal of Adolescent Health : Official Publication of the Society for Adolescent Medicine·L A Linday
Jan 1, 1995·Schizophrenia Research·G D PrellR J Wyatt
Oct 1, 1994·Journal of Pediatric Gastroenterology and Nutrition·D A Kelly
Feb 1, 1995·Journal of the American Academy of Child and Adolescent Psychiatry·R PerryR DeCarlo
Aug 1, 1994·British Heart Journal·R BehrensT Rupprecht
Mar 10, 1994·The New England Journal of Medicine·W T Carpenter, R W Buchanan
Feb 1, 1994·Neurology·E CourchesneO Saitoh
Jun 1, 1993·Archives of General Psychiatry·C T GordonJ L Rapoport
Aug 1, 1995·Clinical Neuropharmacology·R B RosseS I Deutsch
Oct 1, 1995·Journal of Clinical Psychopharmacology·L A LindayJ A Lieberman
Dec 1, 1993·Clinical Neuropharmacology·S I DeutschR J Wyatt
Citations
Jun 16, 2001·Indian Journal of Pediatrics·P J Santosh, G Baird
Nov 4, 2005·Journal of Autism and Developmental Disorders·Craig A EricksonChristopher J McDougle
Mar 23, 2011·Medical Hypotheses·M R Buehler
Jul 23, 1999·Medical Hypotheses·L Sher
Sep 28, 1999·Medical Hypotheses·J R Brasić
Nov 27, 2014·Annals of General Psychiatry·Diego BaronioRudimar Riesgo
Jan 7, 2015·PloS One·Diego BaronioRudimar Riesgo
Jul 7, 2010·Anaerobe·Sydney M FinegoldJohn A Green
Dec 30, 2015·Experimental Neurobiology·Darine Froy N MabungaChan Young Shin
Jul 3, 2020·Frontiers in Pharmacology·Nermin EissaBassem Sadek